Ascendis Pharma A/S (ASND)

Ascendis Pharma External Customers Revenue

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022
Research and Development	255.26M	225.73M	217.85M	209.11M	213.61M	178.66M	131.50M	96.78M
Research and Development Growth	19.50%	26.34%	65.67%	116.06%	227.01%	401.03%	-	-
License	98.98M	122.34M	90.79M	90.51M	90.23M	66.08M	2.41M	2.48M
License Growth	9.69%	85.15%	3,668.91%	3,557.09%	3,467.93%	2,494.31%	-	-
Milestone	14.47M	15.57M	18.79M	18.01M	25.18M	21.98M	18.01M	19.91M
Milestone Growth	-42.54%	-29.16%	4.34%	-9.55%	149.69%	69.48%	-	-

Commercial Products Revenue

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022
Skytrofa	183.29M	196.95M	202.40M	202.20M	211.90M	178.90M	131.90M	97.20M
Skytrofa Growth	-13.50%	10.09%	53.45%	108.02%	222.53%	402.53%	-	-
Yorvipath	58.27M	13.58M	-	-	-	-	-	-

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.